Studying why some chronic lymphocytic leukemia patients respond to BTK degraders
Collects blood samples to study resistance to BTK degraders in leukemia.
Plain-language title generated from the registry record
Registry title: Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Key facts
- Where
- Angers, Bordeaux, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris, Poitiers, and Rouen, FranceSee the 14 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia (CLL) who may start, or have already taken, a BTK degrader. Extra samples are collected to study why these drugs stop working.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Chronic lymphocytic leukemia (CLL). No stage is named.
- Earlier treatment
- The person may be a candidate for a BTK degrader (BTKd) or may have already taken one.
Main reasons for not taking part
- Minors
- Adults under guardianship
- Protected persons
- No social security health insurance cover
- No signed informed consent
Read by machine on 12 November 2026.
Where in France
- CHU de AngersAngers, FranceContact: Aline ClavertNot yet recruiting
- CHU de BordeauxBordeaux, FranceContact: Raphaëlle AubraisNot yet recruiting
- Institut BergonieBordeaux, FranceContact: Fontanet BijouNot yet recruiting
- CHU de Clermont-FerrandClermont-Ferrand, FranceContact: Romain GuiezeNot yet recruiting
- CHD VendéeLa Roche-sur-Yon, FranceContact: Jessie BourcierTaking people
- Centre Léon BernardLyon, FranceContact: Anne-Sophie MichalletNot yet recruiting
- Institut Paoli Calmettes (Marseille)Marseille, FranceNot yet recruiting
- CHU de MontpellierMontpellier, FranceContact: Emmanuelle TchernonogNot yet recruiting
- CH Régional Universitaire de NancyNancy, FranceContact: Pierre FeugierNot yet recruiting
- University HospitalNantes, FranceContact: Anne LOK, MD, PhDTaking people
- Hôpital Avicenne (AP-HP)Paris, FranceContact: Vincent LevyNot yet recruiting
- Hôpital Universitaire Pitié Salpêtrière de ParisParis, FranceContact: Damien Roos WeilNot yet recruiting
- CHU de PoitiersPoitiers, FranceContact: Cécile TomowiakNot yet recruiting
- Centre Henri-Becquerel de RouenRouen, FranceContact: Stéphane LepretreNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07099443
- Record updated
- 8 July 2026
- Original description
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.Read full original descriptionShow less
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
Inclusion: Patient with CLL candidates ou exposed to BTKd; Patient who has provided informed consent to participate in the study; Patient covered by a social security health insurance plan.
Exclusion: Minor patients; Adults under guardianship; Protected persons.